HerinCAR-PD1

N/A

Report date: 2021/12/14 16:37:32

Base Information

Drug NameHerinCAR-PD1
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionProgrammed cell death protein 1 modulatorsT lymphocyte replacements
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsSolid tumoursNeoplasmsMeningitis, Fungal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNingbo Cancer Hospital
China Registration ClassN/A

Develop Information

Active CompaniesNingbo Cancer Hospital
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsNeoplasmsMeningitis, Fungal

Other Information

ATC CodeN/A
Related LinksN/A